Valuation: Quanterix Corporation

Capitalization 353M 301M 281M 264M 487M 31.98B 532M 3.28B 1.27B 15.08B 1.33B 1.3B 55.01B P/E ratio 2025 *
-3.39x
P/E ratio 2026 * -4.95x
Enterprise value 353M 301M 281M 264M 487M 31.98B 532M 3.28B 1.27B 15.08B 1.33B 1.3B 55.01B EV / Sales 2025 *
2.66x
EV / Sales 2026 * 2.09x
Free-Float
92.99%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.13%
1 week-0.92%
Current month+4.13%
1 month+44.83%
3 months+57.17%
6 months+22.13%
Current year-28.88%
More quotes
1 week 7.27
Extreme 7.27
7.81
1 month 5.17
Extreme 5.17
7.88
Current year 4.05
Extreme 4.05
12.41
1 year 4.05
Extreme 4.05
12.41
3 years 4.05
Extreme 4.05
29.7
5 years 4.05
Extreme 4.05
92.57
10 years 4.05
Extreme 4.05
92.57
More quotes
Manager TitleAgeSince
Chief Executive Officer 43 2022-04-24
Director of Finance/CFO 51 2023-08-20
Chief Operating Officer - 2024-05-20
Director TitleAgeSince
Director/Board Member 43 2022-04-24
Director/Board Member 61 2022-06-05
Chairman 63 2025-03-23
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.13%-0.92%-32.26%-43.20% 353M
-1.14%-0.09%+9.01%+0.82% 217B
-0.92%-5.74%-0.44%+98.04% 194B
-2.60%+0.04%-3.48%-17.24% 164B
+0.90%-5.07%+2.39%+96.44% 136B
+0.98%+1.33%-18.05%-12.42% 57.2B
-1.38%-3.61%+12.32%+10.30% 48.88B
-2.23%-3.99%-0.87%-10.08% 40.44B
-2.43%-1.76%+2.85% - 39.2B
-0.05%-1.67%+4.02%+14.20% 36.79B
Average -0.87%-2.15%-2.45%+15.21% 93.45B
Weighted average by Cap. -0.99%-2.36%+1.51%+32.82%
See all sector performances

Financials

2025 *2026 *
Net sales 133M 113M 106M 99.55M 183M 12.04B 200M 1.23B 479M 5.68B 499M 488M 20.71B 169M 144M 134M 126M 233M 15.29B 254M 1.57B 608M 7.21B 633M 620M 26.29B
Net income -94.88M -80.83M -75.5M -71.04M -131M -8.59B -143M -881M -342M -4.05B -356M -348M -14.78B -71.65M -61.04M -57.02M -53.65M -98.77M -6.49B -108M -666M -258M -3.06B -269M -263M -11.16B
Net Debt - -
More financial data * Estimated data
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Employees
471
More about the company
Date Price Change Volume
25-12-12 7.560 $ +0.13% 431,397
25-12-11 7.550 $ -0.92% 361,593
25-12-10 7.620 $ -0.65% 570,655
25-12-09 7.670 $ +1.59% 1,050,287
25-12-08 7.550 $ -1.05% 875,785

Delayed Quote Nasdaq, December 12, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
7.560USD
Average target price
6.000USD
Spread / Average Target
-20.63%
Consensus

Quarterly revenue - Rate of surprise